ABLA
ANGO icon

Alan B. Lancz & Associates’s AngioDynamics ANGO Stock Holding History

Alan B. Lancz & Associates’s Portfolio ANGO Stock Details ANGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-16,350
Closed -$210K – 130
2025
Q4 		$210K Hold
16,350
– – 0.18% 129
2025
Q3 		$183K Buy
16,350
+5,400
+49% +$52.1K 0.17% 130
2025
Q2 		$109K Hold
10,950
– – 0.11% 127
2025
Q1 		$103K Hold
10,950
– – 0.11% 122
2024
Q4 		$100K Sell
10,950
-2,200
-17% -$16.2K 0.1% 126
2024
Q3 		$102K Hold
13,150
– – 0.09% 135
2024
Q2 		$79.6K Buy
+13,150
New +$81.1K 0.08% 125
2023
Q4 		$101K Sell
12,850
-2,600
-17% -$18K 0.11% 131
2023
Q3 		$113K Sell
15,450
-1,200
-7% -$9.98K 0.13% 124
2023
Q2 		$174K Hold
16,650
– – 0.19% 124
2023
Q1 		$172K Hold
16,650
– – 0.18% 136
2022
Q4 		$229K Hold
16,650
– – 0.23% 116
2022
Q3 		$341K Hold
16,650
– – 0.4% 75
2022
Q2 		$378K Hold
16,650
– – 0.37% 78
2022
Q1 		$359K Hold
16,650
– – 0.32% 91
2021
Q4 		$459K Buy
+16,650
New +$459K 0.4% 71

Other funds holding ANGO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
SFM
Systematic Financial Management Teaneck, New Jersey $5.02B AUM 66.06% 1-Year Est. Return
BH
Broadfin Holdings Melville, New York $23.7M AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
WCM
Weber Capital Management San Francisco, California $118M AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BAM
Bastion Asset Management Montreal, Canada $295M AUM 19.08% 1-Year Est. Return

Alan B. Lancz & Associates's ANGO Position: Q1 2026 in Review

Alan B. Lancz & Associates sold out of AngioDynamics (ANGO) in Q1 2026, closing a stake of 16,350 shares — an estimated $210K sold.

Alan B. Lancz & Associates first reported a position in ANGO in Q4 2021 and held it in 16 quarters. The position peaked at $459K in Q4 2021. 147 funds tracked by Wall St. Rank hold ANGO as of Q1 2026.

  • Alan B. Lancz & Associates reported no remaining AngioDynamics position as of Q1 2026 after selling out during the quarter.
  • Alan B. Lancz & Associates sold 16,350 AngioDynamics shares in Q1 2026, an estimated $210K.
  • Alan B. Lancz & Associates first reported a position in AngioDynamics in Q4 2021 and held it in 16 quarters.
  • Alan B. Lancz & Associates's AngioDynamics position peaked at $459K in Q4 2021.
  • 147 funds tracked by Wall St. Rank held AngioDynamics as of Q1 2026.

Based on Alan B. Lancz & Associates's 13F filing for Q1 2026, filed 5 May 2026.